Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | BMC Cancer

Figure 4

From: Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts

Figure 4

Perfusion and oxygenation status of tumours. A, Labelling with the perfusion marker Hoechst 33342 showed that the flow in blood vessels was better in the VEGF tumours compared with the FGF8b and mock tumours, where Hoechst 33342 labelling was detected only in the tumour periphery (Bar 200 μm). Examples of the intratumoral distribution of [18F]EF5 in FGF8b, VEGF and mock tumour sections are shown in B. FGF8b and mock tumours showed mainly peripherally located uptake of [18F]EF5, whereas uptake into VEGF tumours was more uniform throughout the tumours. Uptake intensity is not comparable between these images, since they were not corrected for injected dose or cross-calibrated between separate studies. C, The tumour-to-blood (T/B) uptake ratio of [18F]EF5 (T/B ratio) in FGF8b (n = 11), VEGF (n = 12) and mock (n = 29) tumours is expressed as mean ± SD. Accumulation of [18F]EF5 was significantly lower (p < 0.05) in VEGF tumours compared with mock tumours, whereas no significant difference in T/B ratio was seen between FGF8b and mock tumours. Partial pressures of oxygen (pO2) in VEGF (n = 3), FGF8b (n = 3) and mock (n = 3) tumours are shown in D. The mean values of pO2 measurements are shown as a curve. VEGF tumours were relatively well oxygenated in comparison with FGF8b and mock tumours.

Back to article page